On June 23, 2023, Protagonist Therapeutics, Inc. notified the Nasdaq Stock Market LLC that following the company's Annual Meeting of Stockholders on May 25, 2023, where Sarah Noonberg, M.D., Ph.D. did not stand for re-election, the company has a vacancy on its Audit Committee and intends to rely on the cure period set forth in the Nasdaq Listing Rules while it recruits a new Audit Committee member.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
37.83 USD | +2.94% | +9.65% | +64.98% |
Jul. 03 | Protagonist Therapeutics, Inc.(NasdaqGM:PTGX) added to S&P 1000 | CI |
Jul. 03 | Protagonist Therapeutics, Inc.(NasdaqGM:PTGX) added to S&P 600 Health Care | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+64.98% | 2.16B | |
+25.83% | 46.56B | |
+45.38% | 41.67B | |
+0.69% | 41.16B | |
+30.52% | 32.4B | |
+22.30% | 28.18B | |
-6.35% | 28.1B | |
+49.25% | 14.52B | |
+49.18% | 13.74B | |
+3.45% | 12.17B |
- Stock Market
- Equities
- PTGX Stock
- News Protagonist Therapeutics, Inc.
- Protagonist Therapeutics, Inc. Announces Retirement of Sarah Noonberg as Director